References
1. Pessach I, Resnick I, Shimoni A, Nagler A. G-CSF-primed BM for
allogeneic SCT: Revisited. Bone Marrow Transplant. 2015;50(7):892-898.
doi:10.1038/bmt.2015.25
2. Frangoul H, Nemecek ER, Billheimer D, Pulsipher MA, Khan S, Woolfrey
A, et al. A prospective study of G-CSF-primed bone marrow as a stem-cell
source for allogeneic bone marrow transplantation in children: A
Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Blood.
2007;110(13):4584-4587. doi:10.1182/blood-2007-07-101071
3. Hussein AA, Sharma S, Al-Zaben A, Frangoul H. Safety and feasibility
of granulocyte colony-stimulating factor (G-CSF) primed bone marrow (BM)
using three days of G-CSF priming as stem cell source for pediatric
allogeneic BM transplantation. Pediatr Transplant. 2014;18(6):625-630.
doi:10.1111/petr.12314
4. Levine JE, Wiley J, Kletzel M, Yanik G, Hutchinson RJ, Koehler M,
Neudorf S. Cytokine-Mobilized Allogeneic Peripheral Blood Stem Cell
Transplants in Children Result in Rapid Engraftment and a High Incidence
of Chronic GVHD. Vol 25.; 2000. Accessed February 1, 2021.
www.nature.com/bmt
5. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr, Ringdén
O, et al. Higher mortality after allogeneic peripheral-blood
transplantation compared with bone marrow in children and adolescents:
The histocompatibility and alternate stem cell source working committee
of the International Bone Marrow Transplant Registry. J Clin Oncol.
2004;22(24):4872-4880. doi:10.1200/JCO.2004.02.189
6. Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW,
et al. Transplantation of Marrow Cells From Unrelated Donors for
Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden,
Donor HLA-Matching, and Marrow Cell Dose. Accessed February 1, 2021.
http://ashpublications.org/blood/article-pdf/89/11/4226/1409286/4226.pdf
7. Couban S, Messner HA, Andreou P, Egan B, Price S, Tinker L, et al.
Bone Marrow Mobilized with Granulocyte Colony-Stimulating Factor in
Related Allogeneic Transplant Recipients: A Study of 29 Patients. Biol
Blood Marrow Transplant. 2000;6(4 A):422-427.
doi:10.1016/S1083-8791(00)70033-4
8. Morton J, Hutchins C, Durrant S. Granulocyte-Colony-Stimulating
Factor (G-CSF)-Primed Allogeneic Bone Marrow: Significantly Less
Graft-versus-Host Disease and Comparable Engraftment to G-CSF-Mobilized
Peripheral Blood Stem Cells.; 2001.
9. Becker P, Schwebig A, Brauninger S, Bialleck H, Luxembourg B, Schulz
M, et al. Healthy donor hematopoietic stem cell mobilization with
biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and
graft performance: Biosimilar granulocyte-colony. doi:10.1111/trf.13853
10. Cetean S, Căinap C, Constantin A-M, Căinap S, Gherman A, Oprean L,
et al. The importance of the granulocyte-colony stimulating factor in
oncology. Pharm Clujul Med. 2015;88(4):468-472. doi:10.15386/cjmed-531
11. Avalos B. Molecular analysis of the granulocyte colony-stimulating
factor receptor. Blood. 1996;88(3):761-777.
doi:10.1182/blood.v88.3.761.761
12. Deotare U, Al-Dawsari G, Couban S, Lipton JH. G-CSF-primed bone
marrow as a source of stem cells for allografting: revisiting the
concept. Published online 2015. doi:10.1038/bmt.2015.80
13. Karakukcu M, Unal E. Stem cell mobilization and collection from
pediatric patients and healthy children. Transfus Apher Sci.
2015;53(1):17-22. doi:10.1016/j.transci.2015.05.010
14. Arcese W, De Angelis G, Cerretti R. Granulocyte-mobilized bone
marrow. Curr Opin Hematol. 2012;19(6):448-453.
doi:10.1097/MOH.0b013e32835903ab
15. Isola LM, Scigliano E, Skerrett D, Najfeld V, Fruchtmanet S. A pilot
study of allogeneic bone marrow transplantation using related donors
stimulated with G-CSF. Bone Marrow Transplant. 1997;20(12):1033-1037.
doi:10.1038/sj.bmt.1701029
16. Kim H-J, Min W-S, Cho B-S, Eom KS, Kim SY, Kim YJ, et al. Overcoming
various comorbidities by G-CSF-primed unmanipulated BM SCT in adult
patients with AML. Bone Marrow Transplant. 2009;44:345-351.
doi:10.1038/bmt.2009.42
17. Farhan R, Urbanowska E, Zborowska H, Król, M., Król, M., Torosian,
T, et al. Biosimilar G-CSF versus filgrastim and lenograstim in healthy
unrelated volunteer hematopoietic stem cell donors. Published online
2017. doi:10.1007/s00277-017-3060-4
18. Kayıkçı Ö, Tekgündüz E, Kaya AH, Göker H, Aslan A, İskender D, et
al. Biosimilar filgrastim (leucostim®) have similar efficacy in
steady-state hematopoietic progenitor cell mobilization compared to
original filgrastim (neupogen®) and lenograstim (granocyte®): A
retrospective multicenter study. Transfus Apher Sci. 2017;56(6):832-835.
doi:10.1016/j.transci.2017.11.016
19. Sivgin S, Karakus E, Keklik M, Zararsiz G, Solmaz M, Kaynar L, et
al. Evaluation of the efficacy and safety of original filgrastim
(Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim
(Granocyte®) in CD34+ peripheral hematopoietic stem cell mobilization
procedures for allogeneic hematopoietic stem cell transplant. Transfus
Apher Sci. 2016;54(3):410-415. doi:10.1016/j.transci.2016.03.003